Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
177Lu-labeled DOTA-EB-RGD as a candidate for thyroid cancer therapy
Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska
Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska
View: Text | PDF
Research Article Endocrinology Oncology

177Lu-labeled DOTA-EB-RGD as a candidate for thyroid cancer therapy

  • Text
  • PDF
Abstract

Integrin αVβ3, a transmembrane receptor involved in tumor growth and metastasis, specifically recognizes and binds proteins with the Arg-Gly-Asp (RGD) peptide sequence. Using mRNA and/or protein expression data from 496 thyroid cancer (TC) samples in The Cancer Genome Atlas, 14 TC cell lines, and 70 TC and 10 normal thyroid tissues, we found that papillary TC exhibits the highest αVβ3 integrin expression. We then evaluated the therapeutic efficacy of a radiolabeled RGD analog, 177Lu-DOTA-EB-cRGDfK, in TC. Genetic knockout and overexpression of αVβ3 in TC cell lines confirmed the target specificity of 177Lu-DOTA-EB-cRGDfK. In mouse xenograft models established from human TC cell lines with high αVβ3 expression, 177Lu-DOTA-EB-cRGDfK demonstrated superior antitumor efficacy compared with standard-of-care lenvatinib and placebo. However, no synergistic benefit was observed with combination therapy. Biodistribution studies identified the kidneys as the dose-limiting organ. RNA-seq analysis of resected tumors demonstrated that 177Lu-DOTA-EB-cRGDfK induced a type I IFN response, characterized by upregulation of IFI6, IFIT1-2, and MX1, compared with both lenvatinib-treated tumors and placebo. These findings identify αVβ3 integrin as a promising therapeutic target in a subset of TCs and demonstrate that 177Lu-DOTA-EB-cRGDfK exhibits superior efficacy to lenvatinib, supporting its potential clinical translation for progressive TC refractory to standard therapies.

Authors

Sonam Kumari, Rhitajit Sarkar, Zhantong Wang, Shilpa Thakur, Laura Abaandou, Oksana Gavrilova, Huiyan Lu, Noha Behairy, Lixin Lang, Dale Kiesewetter, Vasyl Vasko, Joanna Klubo-Gwiezdzinska

×

Figure 3

Evaluation of αVβ3 integrin receptor on TC cell surface.

Options: View larger image (or click on image) Download as PowerPoint
Evaluation of αVβ3 integrin receptor on TC cell surface.
(A) Representat...
(A) Representative flow cytometry dot plots (10,000 events acquired; N = 3, n = 3) showing cell-surface expression of integrin αVβ3 in OCUT2 (99% positive, upper panel) and FTC133 (63% positive, lower panel) cells. Red gates indicate αVβ3-positive cells detected by AF633-conjugated secondary antibody fluorescence (APC channel, x-axis) versus side scatter (y-axis). Plots are shown for DAPI, secondary antibody control, and anti-αVβ3–stained cells. (B) Overlay histograms of αVβ3 staining show a greater rightward fluorescence shift in OCUT2 cells compared with FTC133 cells, indicating higher αVβ3 expression. (C) The mean fluorescence intensity (MFI) analysis revealed higher αVβ3 cell surface expression in OCUT2 than in FTC133. The results show an average of N = 4 biological replicate experiments, each done in triplicate (n = 3) and 2-tailed Welch’s t test was performed. (D) The staggered overlay for the univariate histograms of αVβ3 staining for OCUT2-β3KO (blue) over OCUT2 parental cells with secondary (green) and anti-αVβ3 (red) antibodies shows no expression of αVβ3 receptor on the knockout cell surface. The adjacent dot plot quantitatively reveals the significant downregulation in MFI (N = 4, n = 2 or 3, 2-tailed Welch’s t test). (E) Adenoviral overexpression of αVβ3 on FTC133 (red) resulted in a substantial shift of the staggered histogram compared with parental FTC133 (blue) and parental cells with secondary antibody (green). The corresponding MFI analysis showed a significant increase in αVβ3 cell surface expression in the overexpressing cells compared with the parental cells (N = 4, n = 3, 2-tailed Welch’s t test). ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts